Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Gene Activation Mediated by Zinc Finger Transcriptional Regulators (ZF-TRs) as a Therapeutic Approach for CNS Disorders

Download PDF